This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sana Biotechnology has a new $50 million tool in its toolbox. That’s according to a study in Nature Communications led by CRISPR pioneer Feng Zhang at the Broad Institute of MIT and Harvard, which has licensed its technology to Beam. The application with the U.S. Sana CEO and president Steve Harr. Sana Photo).
A biotech prize for turning chemicals into food On the biotechnology front, the Mars Society plans to offer an incentive prize for methods that use microbes to convert simple chemicals, such as methane or methanol, into food. “Ask it anything you want, and you get the answer in multiple personalities,” he said.
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Icosavax filed a clinical trial application in Belgium in June for its RSV candidate and plans to initiate trials later this year, according to a company filing with the U.S. Icosavax Photo).
Under the agreement, Takeda has options to exclusively license programs at the preclinical stage and will take products to the clinic and through commercialization. The company aims to file an investigational new drug application for the condition with the U.S.
Nvidia AI Foundations is a family of cloud services with which enterprises will be able to build their own large language models (LLMs), the technologies at the heart of generative AI systems, and run them at scale, calling them from enterprise applications via Nvidia’s APIs.
And I’ll earn my A-class license on iRacing…. The hottest technology of 2021: We can expect that AI (and generally everything ML-driven) will remain a super hot technology in 2021, especially with applications in medicine and other areas. The hottest technology of 2021: Investments and advances in augmented reality applications.
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content